Jie Liu
Managing Director
New York Office | jie.liu@torreya.com
Jie Liu, a Managing Director at Torreya, leads the company’s operations in China. He has over 20 years of experience in the pharmaceutical and healthcare industries, mostly focused on global licensing and M&A. In his current role, Jie is active in a variety of transactions in both branded and generic opportunities in the US and China.
Jie has done 15 transactions related to China since joining Torreya. Notable transactions include the licensing of China rights for Arbutus’ HBV product to Qilu, JV of Luoxin and Aurobindo in respiratory and licensing of Calliditas’ Tarpeyo for IgA nephropathy to Everest Medicine in the Greater China region.
Jie joined Torreya in 2016 from Heritage Pharma, a subsidiary of Emcure Pharmaceuticals, where he was Vice President, Business Development and Licensing. Previously, he was Senior Director, Global Business Development at Teva, and held business development positions with increasing responsibilities at J&J, Cephalon, and Auxilium.
Jie received a B.A. from Tianjin University in China and an M.B.A. in healthcare from the Wharton School at the University of Pennsylvania. Jie is a native Mandarin speaker.
Selected Transactions
|
| License of Vicineum™ in Greater China Region to |
|
|
$12 million upfront
July 2020
|
|
| License of Feraccru® in China to |
|
|
$62.8 million
January 2020
|
|
| License of NOV03 in North America to |
|
|
December 2019
|
|
| License of Gemcabene in China to |
|
|
July 2019
|
|
| License of Nefecon in Greater China and Singapore to |
|
|
Up to $121 million
June 2019
|
|
| Exclusive licensing and strategic partnership for AB-729 in China with |
|
|
|
$55 million (upfront + equity)
+ $245 million in milestones December 2021
|
|
| Licensing of Budesolv in China to |
|
|
October 2021
|
|
| License agreement for GnRH antagonist Linzagolix in China from |
|
|
September 2021
|
|
| Sale to |
|
|
$260 million
August 2021
|
|
| Out -license of Bredinin™ in Mainland China to |
|
|
June 2021
|
|
| License of Ravicti® in the Greater China Area, South Korea and Southeast Asia by |
|
|
December 2020
|
|
| License of Galinpepimut-S in Greater China by |
|
|
Up to $202 million with $7.5 million upfront
December 2020
|
|
|
| JV Partnership in China with |
|
|
$50 million
December 2018
|
|
| License of Durasert™ in Ophthalmology in the Greater China Region to |
|
|
Up to $11.75 million
November 2018
|
|
| License of AJT-240 in hemodialysis in China to |
|
|
Up to $24 million
June 2018
|